We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Rapid Diagnostic Tests Compared for Invasive Amoebiasis

By LabMedica International staff writers
Posted on 30 Oct 2013
Three rapid immunoassays have been compared and evaluated for the diagnosis of invasive amoebiasis in an emergency department. More...


Sensitive rapid diagnostic tests (RDT) contribute to an early diagnosis and thus improve the prognosis. The test should be also specific to distinguish amoebic and pyogenic abscess in order to avoid a percutaneous drainage for diagnostic purposes and a broad-spectrum antibiotherapy.

Scientists at the Military Teaching Hospital (HIA) Bégin (Saint-Mandé, France) carried out a retrospective biological records review that included 639 patients for whom three serological tests were performed. They compared a latex agglutination test (LAT) with enzyme-linked immunosorbent assay and indirect hemagglutination assay in the diagnosis of invasive amoebiasis (IA) performed from January 1, 2001, to July 1, 2012.

The three different techniques performed for each patient at laboratory of Bégin Hospital were: a latex agglutination slide test (LAT) (Bichrolatex-Amibe, Fumouze Diagnostic; Levallois-Perret, France); an enzyme linked immunosorbent assay (ELISA) (NovaTec Entamoeba histolytica IgG-ELISA, DiaSorin SPA; Saluggia, Italy); and the Fumouze Diagnostic’s indirect hemagglutination assay Amibiase HAI (IHA).

A total of 639 patients with a performed serology were included and among them 75 had at least one positive serological result. Of these 75 patients, 46 had a final diagnosis of IA, 43 with hepatic amoebiasis, two with intestinal amoebomas and one with pleuropulmonary amoebiasis and 29 patients had another final diagnosis. The LAT was statistically more sensitive than ELISA and IHA.

The authors concluded that LAT could be used in any routine clinical laboratory because it is simple to perform and does not require any special equipment. The result is achieved quickly in 15 minutes. The interpretation is easy because the bicolored positive pattern is very distinguishable from a negative brown spot. The cost remains low at approximately EUR 5.22 per test in France. The LAT is a useful screening technique in the rapid diagnosis and the management of patients with febrile hepatalgia in emergency units. However, this test should be systematically confirmed by reference techniques (ELISA, IHA). The study was published on October 11, 2013, in the journal Diagnostic Microbiology and Infectious Disease.

Related Links:

Military Teaching Hospital Bégin
Fumouze Diagnostic 
DiaSorin SPA 



Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Luteinizing Hormone Assay
DRG LH-Serum ELISA Kit
New
Alpha-Fetoprotein Reagent
AFP Reagent Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: AI-analyzed images from the FDM microscope show platelet clumps in motion (Photo courtesy of Hirose et al CC-BY-ND)

AI Microscope Spots Deadly Blood Clots Before They Strike

Platelets are small blood cells that act as emergency responders in the body, rushing to areas of injury to help stop bleeding by forming clots. However, sometimes platelets can overreact, leading to complications.... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.